NEUROCRINE BIOSCIENCES INC (NBIX)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$274.5M
Cash & Equivalents
$145.8M
Quarterly Burn Rate
$15,669M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (2 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
CRINECERFONT
CRENESSITY |
APPROVED | Anhedonia, Basal Ganglia Disease, Bipolar Disorder, Bipolar I Disorder, Brain and Central Nervous System Tumors, Brain Diseases, Breast Cancer, CAH - Congenital Adrenal Hyperplasia, Central Nervous System Diseases, Cerebral Palsy, Chorea, Huntington, Congenital Adrenal Hyperplasia, Continuous Spike and Wave During Sleep, Depression, Depressive Disorder, Developmental Disabilities, Drug-Induced Movement Disorder, Dyskinesia, Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects, Epileptic Encephalopathy, Essential Tremor, Focal Onset Epilepsy, Focal Onset Seizure, Folliculogenesis, Friedreich Ataxia, Healthy, Healthy Volunteers, Idiopathic Parkinson's Disease, Insomnia, Intellectual Disability, Kidney Cancer, Lung Cancer, Major Depressive Disorder, Mania, Movement Disorders, Multiple Sclerosis, Nervous System Diseases, Neurodegenerative Diseases, Obsessive-Compulsive Disorder, Parkinson Disease, Parkinson's Disease, Parkinsonian Disorders, Safety, Tolerability, and PK of NBI-98854 in Hepatically Im |
|
VALBENAZINE TOSYLATE
INGREZZA |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.